{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:08:37Z","timestamp":1788390517149,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Immunotherapy has become a new therapy for advanced hepatocellular carcinoma (HCC); however, its treatment results are considerably different. CD4+ T cells (CD4+) are the key to immunotherapy, but patients with HCC that have low CD4+ are rarely observed for clinical evidence. Hepatitis B virus-related HCC is often accompanied by cirrhosis and portal hypertension; therefore, CD4+ tend to be relatively low in number. TACE is the standard treatment for Barcelona Clinic Liver Cancer (BCLC)-B HCC, which may further reduce the number of CD4\u2009+\u2009.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective cohort study further reduced CD4+ by including patients with human immunodeficiency virus (HIV) to observe the relationship between CD4+ and Chronic hepatitis B virus (CHB) induced HCC. A total of 170 BCLC-B HCC patients (42 HIV+) were included. Univariate and multivariate analyses, and artificial neural networks (ANNs) were used to evaluate the independent risk factors for the two-year survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The statistical analysis of the two-year survival rate showed that the main factors influencing survival were liver function and immune indices, including CD4+, platelet, alanine aminotransferase, aspartate aminotransferase, aspartate aminotransferase-to-platelet ratio index, and fibrosis-4 (FIB-4) (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Compared with that in other indices, in logistic and ANN multivariate analysis, CD4\u2009+\u2009-to-FIB-4 ratio (CD4+\/FIB-4) had the highest importance with 0.716 C-statistic and 145.93 cut-off value. In terms of overall survival rate, HIV infection was not a risk factor (<jats:italic>P<\/jats:italic>\u2009=\u20090.589); however, CD4+\/FIB-4\u2009\u2264\u2009145.93 significantly affected patient prognosis (<jats:italic>P<\/jats:italic>\u2009=\u20090.002).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>HIV infection does not affect the prognosis of BCLC-B HCC, but CD4+ have a significant predictive value. CD4+ played a vital role in HCC and this deserves the attention from physicians. Further, the CD4+\/FIB-4 is a clinically valuable effective prognostic indicator for these patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-09433-3","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T09:08:57Z","timestamp":1648026537000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A simple CD4+ T cells to FIB-4 ratio for evaluating prognosis of BCLC-B hepatocellular carcinoma: a retrospective cohort study"],"prefix":"10.1186","volume":"22","author":[{"given":"Yong","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling Xiang","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng Shi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,23]]},"reference":[{"key":"9433_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.21037\/sci-2021-029","volume":"8","author":"L Biglow","year":"2021","unstructured":"Biglow L, Ashraf S, Alsharedi M. Checkpoint inhibitors: literature review of new treatments for hepatocellular carcinoma. Stem Cell Investig. 2021;8:22.","journal-title":"Stem Cell Investig"},{"issue":"4","key":"9433_CR2","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1073\/pnas.0910341107","volume":"107","author":"N Jain","year":"2010","unstructured":"Jain N, Nguyen H, Chambers C, Kang J. Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proc Natl Acad Sci U S A. 2010;107(4):1524\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9433_CR3","doi-asserted-by":"publisher","first-page":"806043","DOI":"10.3389\/fimmu.2021.806043","volume":"12","author":"Y Hao","year":"2021","unstructured":"Hao Y, Cook MC. Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1. Front Immunol. 2021;12:806043.","journal-title":"Front Immunol"},{"key":"9433_CR4","doi-asserted-by":"publisher","first-page":"808101","DOI":"10.3389\/fimmu.2022.808101","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Lu L, He Z, Xu Z, Xiang Z, Nie RC, et al. C-Reactive Protein Levels Predict Responses to PD-1 Inhibitors in Hepatocellular Carcinoma Patients. Front Immunol. 2022;13:808101.","journal-title":"Front Immunol"},{"key":"9433_CR5","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.3389\/fimmu.2019.02048","volume":"10","author":"Y Chen","year":"2019","unstructured":"Chen Y, Tian Z. HBV-Induced Immune Imbalance in the Development of HCC. Front Immunol. 2019;10:2048.","journal-title":"Front Immunol"},{"issue":"12","key":"9433_CR6","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1084\/jem.188.12.2199","volume":"188","author":"SA Kalams","year":"1998","unstructured":"Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med. 1998;188(12):2199\u2013204.","journal-title":"J Exp Med"},{"issue":"7","key":"9433_CR7","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3748\/wjg.14.1112","volume":"14","author":"J You","year":"2008","unstructured":"You J, Sriplung H, Geater A, Chongsuvivatwong V, Zhuang L, Chen HY, et al. Effect of viral load on T-lymphocyte failure in patients with chronic hepatitis B. World J Gastroenterol. 2008;14(7):1112\u20139.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"9433_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/hep.26054","volume":"58","author":"J Fu","year":"2013","unstructured":"Fu J, Zhang Z, Zhou L, Qi Z, Xing S, Lv J, et al. Impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. Hepatology. 2013;58(1):139\u201349.","journal-title":"Hepatology."},{"issue":"6","key":"9433_CR9","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s10147-010-0131-0","volume":"15","author":"K Shirabe","year":"2010","unstructured":"Shirabe K, Motomura T, Muto J, Toshima T, Matono R, Mano Y, et al. Tumor-infiltrating lymphocytes and hepatocellular carcinoma: pathology and clinical management. Int J Clin Oncol. 2010;15(6):552\u20138.","journal-title":"Int J Clin Oncol"},{"issue":"18","key":"9433_CR10","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1200\/JCO.2006.09.4565","volume":"25","author":"Q Gao","year":"2007","unstructured":"Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25(18):2586\u201393.","journal-title":"J Clin Oncol"},{"issue":"1","key":"9433_CR11","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3892\/ol.2021.12815","volume":"22","author":"J Guo","year":"2021","unstructured":"Guo J, Wang S, Han Y, Jia Z, Wang R. Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma. Oncol Lett. 2021;22(1):554.","journal-title":"Oncol Lett"},{"issue":"1","key":"9433_CR12","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/hep.27382","volume":"61","author":"G Xiao","year":"2015","unstructured":"Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology. 2015;61(1):292\u2013302.","journal-title":"Hepatology."},{"issue":"1","key":"9433_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jhep.2018.10.011","volume":"70","author":"M Cornberg","year":"2019","unstructured":"Cornberg M, Tacke F, Karlsen TH. Clinical Practice Guidelines of the European Association for the study of the Liver - Advancing methodology but preserving practicability. J Hepatol. 2019;70(1):5\u20137.","journal-title":"J Hepatol"},{"issue":"3","key":"9433_CR14","doi-asserted-by":"publisher","first-page":"R117","DOI":"10.1186\/cc9068","volume":"14","author":"CE Oberkofler","year":"2010","unstructured":"Oberkofler CE, Dutkowski P, Stocker R, Schuepbach RA, Stover JF, Clavien PA, et al. Model of end stage liver disease (MELD) score greater than 23 predicts length of stay in the ICU but not mortality in liver transplant recipients. Critical Care (London, England). 2010;14(3):R117.","journal-title":"Critical Care (London, England)"},{"issue":"4","key":"9433_CR15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.5582\/bst.2017.01202","volume":"11","author":"P Song","year":"2017","unstructured":"Song P, Cai Y, Tang H, Li C, Huang J. The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines from 2001 to 2017. Biosci Trends. 2017;11(4):389\u201398.","journal-title":"Biosci Trends"},{"issue":"4","key":"9433_CR16","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1053\/j.gastro.2015.12.041","volume":"150","author":"J Bruix","year":"2016","unstructured":"Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;150(4):835\u201353.","journal-title":"Gastroenterology."},{"issue":"2","key":"9433_CR17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/jhep.2003.50047","volume":"37","author":"JM Llovet","year":"2003","unstructured":"Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37(2):429\u201342.","journal-title":"Hepatology."},{"key":"9433_CR18","doi-asserted-by":"crossref","unstructured":"Jeon D, Choi WM, Kim JS, Jung Y, Lee SY, Seo HR, et al. Serum Sorbitol Dehydrogenase as a Novel Prognostic Factor for Hepatocellular Carcinoma after Surgical Resection. Cancers (Basel). 2021;13(23).","DOI":"10.3390\/cancers13236143"},{"issue":"12","key":"9433_CR19","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","volume":"3","author":"T Akinyemiju","year":"2017","unstructured":"Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol. 2017;3(12):1683\u201391.","journal-title":"JAMA Oncol"},{"issue":"8","key":"9433_CR20","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1158\/0008-5472.CAN-13-2269","volume":"74","author":"I P\u00e9guillet","year":"2014","unstructured":"P\u00e9guillet I, Milder M, Louis D, Vincent-Salomon A, Dorval T, Piperno-Neumann S, et al. High numbers of differentiated effector CD4 T cells are found in patients with cancer and correlate with clinical response after neoadjuvant therapy of breast cancer. Cancer Res. 2014;74(8):2204\u201316.","journal-title":"Cancer Res"},{"issue":"1","key":"9433_CR21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.bbrc.2015.01.069","volume":"458","author":"Q Zhang","year":"2015","unstructured":"Zhang Q, Jia Q, Deng T, Song B, Li L. Heterogeneous expansion of CD4+ tumor-infiltrating T-lymphocytes in clear cell renal cell carcinomas. Biochem Biophys Res Commun. 2015;458(1):70\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"9433_CR22","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/jcla.21532","volume":"26","author":"F Lang","year":"2012","unstructured":"Lang F, Linlin M, Ye T, Yuhai Z. Alterations of dendritic cell subsets and TH1\/TH2 cytokines in the peripheral circulation of patients with superficial transitional cell carcinoma of the bladder. J Clin Lab Anal. 2012;26(5):365\u201371.","journal-title":"J Clin Lab Anal"},{"issue":"7","key":"9433_CR23","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0145-2126(01)00194-1","volume":"26","author":"M Podhorecka","year":"2002","unstructured":"Podhorecka M, Dmoszynska A, Rolinski J, Wasik E. T type 1\/type 2 subsets balance in B-cell chronic lymphocytic leukemia--the three-color flow cytometry analysis. Leuk Res. 2002;26(7):657\u201360.","journal-title":"Leuk Res"},{"issue":"6","key":"9433_CR24","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41419-018-0687-6","volume":"9","author":"ZJ Brown","year":"2018","unstructured":"Brown ZJ, Fu Q, Ma C, Kruhlak M, Zhang H, Luo J, et al. Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4(+) T cell apoptosis promoting HCC development. Cell Death Dis. 2018;9(6):620.","journal-title":"Cell Death Dis"},{"issue":"7593","key":"9433_CR25","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nature16969","volume":"531","author":"C Ma","year":"2016","unstructured":"Ma C, Kesarwala AH, Eggert T, Medina-Echeverz J, Kleiner DE, Jin P, et al. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature. 2016;531(7593):253\u20137.","journal-title":"Nature."},{"issue":"3\u20134","key":"9433_CR26","first-page":"429","volume":"59","author":"L Wang","year":"2013","unstructured":"Wang L, Shen Y. Imbalance of circulating T-lymphocyte subpopulation in gastric cancer patients correlated with performance status. Cl\u00edn Lab. 2013;59(3\u20134):429\u201333.","journal-title":"Cl\u00edn Lab"},{"issue":"5","key":"9433_CR27","doi-asserted-by":"publisher","first-page":"e1004078","DOI":"10.1371\/journal.ppat.1004078","volume":"10","author":"S Serrano-Villar","year":"2014","unstructured":"Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, et al. HIV-infected individuals with low CD4\/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 2014;10(5):e1004078.","journal-title":"PLoS Pathog"},{"key":"9433_CR28","doi-asserted-by":"crossref","unstructured":"Kalathil SG, Lugade AA, Miller A, Iyer R, Thanavala Y. PD-1(+) and Foxp3(+) T cell reduction correlates with survival of HCC patients after sorafenib therapy. JCI Insight. 2016;1(11).","DOI":"10.1172\/jci.insight.86182"},{"issue":"7","key":"9433_CR29","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/jnci\/djz214","volume":"112","author":"J Torgersen","year":"2020","unstructured":"Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D'Addeo K, et al. HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status. J Natl Cancer Inst. 2020;112(7):747\u201355.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"9433_CR30","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/hep.25800","volume":"57","author":"GN Ioannou","year":"2013","unstructured":"Ioannou GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology. 2013;57(1):249\u201357.","journal-title":"Hepatology."},{"issue":"5","key":"9433_CR31","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/COH.0000000000000292","volume":"11","author":"MB Klein","year":"2016","unstructured":"Klein MB, Rockstroh JK, Wittkop L. Effect of coinfection with hepatitis C virus on survival of individuals with HIV-1 infection. Curr Opin HIV AIDS. 2016;11(5):521\u20136.","journal-title":"Curr Opin HIV AIDS"},{"issue":"5","key":"9433_CR32","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3748\/wjg.v24.i5.613","volume":"24","author":"PDS Marcon","year":"2018","unstructured":"Marcon PDS, Tovo CV, Kliemann DA, Fisch P, de Mattos AA. Incidence of hepatocellular carcinoma in patients with chronic liver disease due to hepatitis B or C and coinfected with the human immunodeficiency virus: A retrospective cohort study. World J Gastroenterol. 2018;24(5):613\u201322.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"9433_CR33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.7326\/0003-4819-146-2-200701160-00003","volume":"146","author":"N Lohse","year":"2007","unstructured":"Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2007;146(2):87\u201395.","journal-title":"Ann Intern Med"},{"issue":"1","key":"9433_CR34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/QCO.0b013e32835ba6b1","volume":"26","author":"F Nakagawa","year":"2013","unstructured":"Nakagawa F, May M, Phillips A. Life expectancy living with HIV: recent estimates and future implications. Curr Opin Infect Dis. 2013;26(1):17\u201325.","journal-title":"Curr Opin Infect Dis"},{"issue":"4","key":"9433_CR35","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/hiv.12204","volume":"16","author":"E Rosenthal","year":"2015","unstructured":"Rosenthal E, Roussillon C, Salmon-Ceron D, Georget A, Henard S, Huleux T, et al. Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 Mortalite 2010 survey. HIV Med. 2015;16(4):230\u20139.","journal-title":"HIV Med"},{"issue":"4","key":"9433_CR36","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/cid\/cix392","volume":"65","author":"EA Engels","year":"2017","unstructured":"Engels EA, Yanik EL, Wheeler W, Gill MJ, Shiels MS, Dubrow R, et al. Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America. Clin Infect Dis. 2017;65(4):636\u201343.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"9433_CR37","doi-asserted-by":"publisher","first-page":"507","DOI":"10.7326\/M14-2768","volume":"163","author":"MJ Silverberg","year":"2015","unstructured":"Silverberg MJ, Lau B, Achenbach CJ, Jing Y, Althoff KN, D'Souza G, et al. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med. 2015;163(7):507\u201318.","journal-title":"Ann Intern Med"},{"issue":"24","key":"9433_CR38","doi-asserted-by":"publisher","first-page":"6226","DOI":"10.1002\/cncr.27694","volume":"118","author":"VV Sahasrabuddhe","year":"2012","unstructured":"Sahasrabuddhe VV, Shiels MS, McGlynn KA, Engels EA. The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States. Cancer. 2012;118(24):6226\u201333.","journal-title":"Cancer."},{"issue":"2","key":"9433_CR39","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/QAI.0000000000000289","volume":"67","author":"MA Kowalkowski","year":"2014","unstructured":"Kowalkowski MA, Day RS, Du XL, Chan W, Chiao EY. Cumulative HIV viremia and non-AIDS-defining malignancies among a sample of HIV-infected male veterans. J Acquir Immune Defic Syndr. 2014;67(2):204\u201311.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"9433_CR40","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1097\/QAI.0000000000000494","volume":"68","author":"JR Kramer","year":"2015","unstructured":"Kramer JR, Kowalkowski MA, Duan Z, Chiao EY. The effect of HIV viral control on the incidence of hepatocellular carcinoma in veterans with hepatitis C and HIV coinfection. J Acquir Immune Defic Syndr. 2015;68(4):456\u201362.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"9433_CR41","doi-asserted-by":"publisher","first-page":"87","DOI":"10.7326\/M16-2094","volume":"169","author":"LS Park","year":"2018","unstructured":"Park LS, Tate JP, Sigel K, Brown ST, Crothers K, Gibert C, et al. Association of Viral Suppression With Lower AIDS-Defining and Non-AIDS-Defining Cancer Incidence in HIV-Infected Veterans: A Prospective Cohort Study. Ann Intern Med. 2018;169(2):87\u201396.","journal-title":"Ann Intern Med"},{"issue":"1","key":"9433_CR42","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41598-020-80311-3","volume":"11","author":"L Kong","year":"2021","unstructured":"Kong L, Wei G, Lv T, Jiang L, Yang J, Zhao Y, et al. Outcome of TACE treatment in HIV infected patients with hepatocellular carcinoma. Sci Rep. 2021;11(1):696.","journal-title":"Sci Rep"},{"issue":"9","key":"9433_CR43","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1634\/theoncologist.2010-0400","volume":"16","author":"M Berretta","year":"2011","unstructured":"Berretta M, Garlassi E, Cacopardo B, Cappellani A, Guaraldi G, Cocchi S, et al. Hepatocellular carcinoma in HIV-infected patients: check early, treat hard. Oncologist. 2011;16(9):1258\u201369.","journal-title":"Oncologist."},{"issue":"1","key":"9433_CR44","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/liv.13921","volume":"39","author":"M Gelu-Simeon","year":"2019","unstructured":"Gelu-Simeon M, Lewin M, Ostos M, Bayan T, Beso Delgado M, Teicher E, et al. Prognostic factors of survival in HIV\/HCV co-infected patients with hepatocellular carcinoma: The CARCINOVIC Cohort. Liver Int. 2019;39(1):136\u201346.","journal-title":"Liver Int"},{"issue":"37","key":"9433_CR45","doi-asserted-by":"publisher","first-page":"8314","DOI":"10.3748\/wjg.v22.i37.8314","volume":"22","author":"HW Lee","year":"2016","unstructured":"Lee HW, Ahn SH. Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients. World J Gastroenterol. 2016;22(37):8314\u201321.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"9433_CR46","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/apt.14356","volume":"47","author":"DJ Pinato","year":"2018","unstructured":"Pinato DJ, Sharma R, Citti C, Platt H, Ventura-Cots M. The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma. Aliment Pharmacol Ther. 2018;47(1):95\u2013103.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"9433_CR47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/cld.728","volume":"12","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Clin Liver Dis (Hoboken). 2018;12(1):33\u20134.","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"9433_CR48","doi-asserted-by":"crossref","unstructured":"Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol. 2019;25(2):93\u2013159.","DOI":"10.3350\/cmh.2019.1002"},{"key":"9433_CR49","doi-asserted-by":"crossref","unstructured":"EASL. 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u201398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"9433_CR50","doi-asserted-by":"publisher","first-page":"9996358","DOI":"10.1155\/2021\/9996358","volume":"2021","author":"L Yang","year":"2021","unstructured":"Yang L, Wang Q, Cui T, Huang J, Jin H. Reporting and Performance of Hepatocellular Carcinoma Risk Prediction Models: Based on TRIPOD Statement and Meta-Analysis. Can J Gastroenterol Hepatol. 2021;2021:9996358.","journal-title":"Can J Gastroenterol Hepatol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09433-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-09433-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09433-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T22:03:37Z","timestamp":1666476217000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-09433-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,23]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["9433"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-09433-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,23]]},"assertion":[{"value":"23 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by the Ethics Committee of the West China Hospital of Sichuan University and written informed consent was obtained from all patients for their data to be used in this research. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/ or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"311"}}